As of June 30, 2024, Cingulate had $0.4 million in cash and cash equivalents. On July 1, 2024, Cingulate received the net proceeds of $1.6 million from the warrant inducement described above. Management believes this cash on hand will support operating and development costs late into the third quarter of 2024. Management intends to seek opportunities to access additional capital as needed, including non-dilutive capital in terms of potential licensing opportunities inside and outside of the US, and additional equity or debt capital.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
- Cingulate Inc trading halted, news pending
- Cingulate files to sell 6.63M shares of common stock for holders
- Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
- Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event